Consensus Celcuity Inc.

Stocks

CELC

US15102K1007

Biotechnology & Medical Research

Market Closed - Nasdaq 00:00:00 17/09/2026 +04			5-day change	1st Jan Change
82.58 ^USD	-0.15%		-8.33%	-17.20%

09-09	Celcuity Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08:00 AM
08-26	Celcuity Inc Submits Supplemental New Drug Application to Fda for Revtorpyk (Gedatolisib) for Hr+/Her2-, Pik3ca Mutant Locally Advanced or Metastatic Breast Cancer	CI

Evolution of the Average Target: Celcuity Inc.

Evolution of the Target Price: Celcuity Inc.

Changes in Analyst Recommendations: Celcuity Inc.

0a8f432cb2c17ee1de2d4b1a415.eu7oKMFzqzJrB1N42Dzexw1nU5rQ8kiiwM2nyIpe7bU.NdyhQLYB_FpdMww8mQ2cj3QkK-uoswuU7bSVm-duhc9LqqVG8BnfRCxyNA~6cce42dbb46251ce56c687e9b68dc44a

Analysts' recommendations: Celcuity Inc.

05-04	U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower	RE
05-04	HC Wainwright Upgrades Celcuity to Buy From Neutral, Adjusts Price Target to $165 From $94	MT
12-12	Wells Fargo Initiates Celcuity With Overweight Rating, $126 Price Target	MT
11-18	Celcuity Shares Fall After HC Wainwright Downgrade	MT
11-17	HC Wainwright Downgrades Celcuity to Neutral From Buy, Adjusts PT to $94 From $77	MT
11-17	HC Wainwright Downgrades Celcuity to Neutral From Buy, Price Target is $94	MT
11-13	Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share	RE
18/10/25	Celcuity Provides Update on Status of the Pik3ca Mutated Cohort of Phase 3 Viktoria-1 Trial and Releases Additional Data Analysis from Phase 1B Clinical Trial	CI
22/09/25	Guggenheim Initiates Celcuity at Buy With $110 Price Target	MT
26/08/24	LifeSci Capital Initiates Coverage on Celcuity With Outperform Rating, $27 Price Target	MT
22/07/24	Leerink Partners Starts Celcuity With Outperform Rating, $29 Price Target	MT
31/05/24	Needham Trims Price Target on Celcuity to $23 From $24, Maintains Buy Rating	MT
16/05/24	Craig-Hallum Adjusts Price Target on Celcuity to $27 From $25, Assumes Buy Rating	MT
28/03/24	Craig Hallum Adjusts Celcuity Price Target to $25 From $20, Maintains Buy Rating	MT
28/03/24	Needham Adjusts Price Target on Celcuity to $24 From $23, Keeps Buy Rating	MT
22/02/24	Stifel Initiates Celcuity With Buy Rating, Price Target is $40	MT
08/12/23	HC Wainwright Starts Coverage on Celcuity with Buy Rating, $27 Price Target	MT
17/05/22	Craig Hallum Adjusts Celcuity Price Target to $20 From $30, Maintains Buy Rating	MT
17/05/22	Needham Adjusts Celcuity's Price Target to $25 from $50, Keeps Buy Rating	MT
08/10/21	Celcuity : Canaccord Genuity Starts Celcuity at Buy With $50 Price Target	MT
07/09/21	Celcuity : Jefferies Starts Celcuity at Buy with $48 Price Target	MT
29/07/21	Celcuity : Cowen Initiates Coverage on Celcuity With Outperform Rating	MT
27/07/21	Celcuity : Needham Starts Celcuity at Buy With $50 Price Target	MT
12/04/21	Celcuity : HC Wainwright Adjusts Celcuity's Price Target to $30 From $19, Maintains Buy Rating	MT
17/02/21	Celcuity : Craig-Hallum Adjusts Celcuity's Price Target to $24 From $19, Reiterates Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CELCUITY INC.					+95.07%
	WUXI APPTEC CO., LTD.					+18.61%
	ARGENX SE					+20.4%
	INSMED INCORPORATED					+62.79%
	WUXI BIOLOGICS (CAYMAN) INC.					+16.41%
	BIONTECH SE					+23.92%
	GENMAB A/S					+10.98%
	PHARMAESSENTIA CORPORATION					+15.96%
	EXELIXIS, INC.					-5.45%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+34.53%
	Average					+29.32%
	Weighted average by Cap.					+23.53%